RT Journal Article
SR Electronic
T1 Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma
JF Neurosciences Journal
JO Neurosciences (Riyadh)
FD Prince Sultan Military Medical City
SP 349
OP 355
VO 18
IS 4
A1 Alnaami, Ibrahim M.
A1 Al-Nuaimi, Saleem K.
A1 Senthilselvan, Ambikaipakan
A1 Murtha, Albert D.
A1 Walling, Simon
A1 Mehta, Vivek
A1 Gourishankar, Sita
YR 2013
UL http://nsj.org.sa/content/18/4/349.abstract
AB OBJECTIVE: To examine whether adjuvant temozolomide treatment improved glioblastoma patients’ survival in a large Canadian cohort.METHODS: We retrospectively studied 364 glioblastoma patients who received different modalities of treatment in 2 Canadian tertiary care centers in Edmonton and Halifax, Canada, between January 2000 and December 2006. The primary outcome was survival following the treatment protocol.RESULTS: The following variables were associated with an increased risk of death: The hazard risk (HR) of on-gross total resection was 0.50 (95% confidence interval [CI]: 0.39-0.64). The HR for the surgery-only group was 5.2 (95% CI: 3.85-7.06). The standard treatment group (surgery, radiation therapy [RT], and temozolomide) had an HR of 0.52 (95% CI: 0.37-0.74). The HR for patients who presented with seizure or whose presentation included seizures was 0.88 (95% CI: 0.55-0.89). Patient entry into trials had an HR of 0.74 (95% CI: 0.57-0.96). Finally, the HR for age was 1.02 (95% CI: 1.01-1.03) for every extra year.CONCLUSION: Concomitant temozolomide with RT and surgery was associated with longer survival compared with RT with surgery alone. We also found that younger age, surgical resection, seizure presence, and entry into trials are important prognostic factors for longer survival.